RARE vs. ROKU

Last updated Apr 2, 2026

Compare and contrast key facts about Ultragenyx Pharmaceutical Inc. (RARE) and Roku, Inc. (ROKU).

Performance

RARE vs. ROKU - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Ultragenyx Pharmaceutical Inc. (RARE) and Roku, Inc. (ROKU). The values are adjusted to include any dividend payments, if applicable.

RARE vs. ROKU - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
RARE Ultragenyx Pharmaceutical Inc.	-6.87%	-45.33%	-12.02%	3.22%	-44.90%	-39.25%	224.12%	-1.77%	-6.25%	-14.08%
ROKU Roku, Inc.	-12.53%	45.94%	-18.90%	125.21%	-82.16%	-31.27%	147.96%	337.01%	-40.83%	120.34%

Fundamentals

Market Cap RARE : $2.14B ROKU : $14.45B
EPS RARE : -$5.79 ROKU : $0.59
PS Ratio RARE : 3.16 ROKU : 3.02
PB Ratio RARE : 132.43 ROKU : 5.44
Total Revenue (TTM) RARE : $672.72M ROKU : $4.74B
Gross Profit (TTM) RARE : $564.07M ROKU : $2.07B
EBITDA (TTM) RARE : -$488.57M ROKU : $263.25M

Returns By Period

In the year-to-date period, RARE achieves a -6.87% return, which is significantly higher than ROKU's -12.53% return.

RARE

• 1D: 2.24%
• 1M: -6.95%
• YTD: -6.87%
• 6M: -28.58%
• 1Y: -36.70%
• 3Y*: -18.86%
• 5Y*: -28.32%
• 10Y*: -10.71%

ROKU

• 1D: 0.30%
• 1M: -3.25%
• YTD: -12.53%
• 6M: -8.37%
• 1Y: 34.42%
• 3Y*: 12.97%
• 5Y*: -22.15%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

RARE vs. ROKU — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

RARE

RARE Risk / Return Rank: 18
RARE Sharpe Ratio Rank: 18
RARE Sortino Ratio Rank: 23
RARE Omega Ratio Rank: 21
RARE Calmar Ratio Rank: 14
RARE Martin Ratio Rank: 12

ROKU

ROKU Risk / Return Rank: 64
ROKU Sharpe Ratio Rank: 64
ROKU Sortino Ratio Rank: 60
ROKU Omega Ratio Rank: 60
ROKU Calmar Ratio Rank: 67
ROKU Martin Ratio Rank: 68

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

RARE vs. ROKU - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Ultragenyx Pharmaceutical Inc. (RARE) and Roku, Inc. (ROKU). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	RARE	ROKU	Difference
Sharpe ratio Return per unit of total volatility	-0.51	0.65	-1.17
Sortino ratio Return per unit of downside risk	-0.27	1.20	-1.47
Omega ratio Gain probability vs. loss probability	0.95	1.16	-0.21
Calmar ratio Return relative to maximum drawdown	-0.74	1.25	-1.99
Martin ratio Return relative to average drawdown	-1.39	3.28	-4.67
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

RARE vs. ROKU - Sharpe Ratio Comparison

The current RARE Sharpe Ratio is -0.51, which is lower than the ROKU Sharpe Ratio of 0.65. The chart below compares the historical Sharpe Ratios of RARE and ROKU, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	RARE	ROKU	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	-0.51	0.65	-1.17
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.53	-0.33	-0.19
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.19	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.09	0.24	-0.33

Correlation

The correlation between RARE and ROKU is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

RARE vs. ROKU - Dividend Comparison

Neither RARE nor ROKU has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

RARE vs. ROKU - Drawdown Comparison

The maximum RARE drawdown since its inception was -89.57%, roughly equal to the maximum ROKU drawdown of -91.91%. Use the drawdown chart below to compare losses from any high point for RARE and ROKU.

Drawdown Indicators

	RARE	ROKU	Difference
Max Drawdown Largest peak-to-trough decline	-89.57%	-91.91%	+2.34%
Max Drawdown (1Y) Largest decline over 1 year	-55.36%	-27.69%	-27.67%
Max Drawdown (5Y) Largest decline over 5 years	-84.01%	-91.91%	+7.90%
Max Drawdown (10Y) Largest decline over 10 years	-89.57%	—	—
Current Drawdown Current decline from peak	-87.92%	-80.21%	-7.71%
Average Drawdown Average peak-to-trough decline	-54.29%	-52.34%	-1.95%
Ulcer Index Depth and duration of drawdowns from previous peaks	29.35%	10.58%	+18.77%

Volatility

RARE vs. ROKU - Volatility Comparison

Ultragenyx Pharmaceutical Inc. (RARE) has a higher volatility of 18.41% compared to Roku, Inc. (ROKU) at 15.13%. This indicates that RARE's price experiences larger fluctuations and is considered to be riskier than ROKU based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	RARE	ROKU	Difference
Volatility (1M) Calculated over the trailing 1-month period	18.41%	15.13%	+3.28%
Volatility (6M) Calculated over the trailing 6-month period	67.91%	32.06%	+35.85%
Volatility (1Y) Calculated over the trailing 1-year period	71.88%	52.86%	+19.02%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	54.12%	67.15%	-13.03%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	55.60%	73.96%	-18.36%

Financials

RARE vs. ROKU - Profitability Comparison

The chart below illustrates the profitability comparison between Ultragenyx Pharmaceutical Inc. and Roku, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

RARE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Ultragenyx Pharmaceutical Inc. reported a gross profit of 178.00M and revenue of 207.00M. Therefore, the gross margin over that period was 86.0%.

ROKU - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Roku, Inc. reported a gross profit of 606.82M and revenue of 1.39B. Therefore, the gross margin over that period was 43.5%.

RARE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Ultragenyx Pharmaceutical Inc. reported an operating income of -114.00M and revenue of 207.00M, resulting in an operating margin of -55.1%.

ROKU - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Roku, Inc. reported an operating income of 65.97M and revenue of 1.39B, resulting in an operating margin of 4.7%.

RARE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Ultragenyx Pharmaceutical Inc. reported a net income of -129.00M and revenue of 207.00M, resulting in a net margin of -62.3%.

ROKU - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Roku, Inc. reported a net income of 80.48M and revenue of 1.39B, resulting in a net margin of 5.8%.